Core Viewpoint - The company, 汇聚科技 (01729), has successfully completed a placement of 108 million shares, raising approximately HKD 1.635 billion, with the funds allocated for strategic investments, global business expansion, and operational needs [1]. Group 1: Placement Details - The placement involved 108 million shares, representing about 5.45% of the company's existing issued share capital prior to the placement and approximately 5.16% after the placement [1]. - The shares were successfully placed at a price of HKD 15.22 per share, with a net issuance price of approximately HKD 15.13 per share after deducting related expenses [1]. Group 2: Use of Proceeds - Approximately 50% of the net proceeds will be used to support the company's strategic investments and acquisitions [1]. - About 30% of the funds will be allocated for the development of global business and expansion into overseas markets [1]. - The remaining 20% will be utilized for working capital and general corporate purposes to support the company's operations and growth [1].

Core Viewpoint - MIRXES-B (02629) successfully completed a share placement, raising approximately HKD 711 million, with a net amount of about HKD 673 million after costs [1] Group 1: Share Placement Details - The board announced that all conditions for the share placement were met, and the delivery occurred on February 5, 2026 [1] - A total of 21.88 million shares were successfully placed at a price of HKD 32.50 per share [1] - The placement was made to no fewer than six independent subscribers, ensuring that they and their ultimate beneficial owners are independent of the company [1] Group 2: Use of Proceeds - Approximately 30% of the net proceeds will be used for investment and acquisition activities [1] - About 25% will be allocated for research and development, including clinical studies of existing pipelines and development of new pipelines [1] - Approximately 20% will be used to expand into emerging markets [1] - The remaining 25% will be utilized for general working capital purposes [1]

Group 1 - The core point of the article is that Kexuan Power Holdings (00476.HK) has completed a placement of 20 million shares at a price of HKD 0.78 per share, with net proceeds of approximately HKD 15.4 million [1] - The placement was made to no less than six subscribers, and all conditions precedent of the placement agreement have been fulfilled [1] - The company plans to use the net proceeds for general working capital, with approximately HKD 12 million allocated for the development and expansion of its new energy business, particularly in electric commercial solutions [1][1] Group 2 - An additional HKD 3.4 million from the net proceeds will be used to supplement the company's general working capital [1]

Group 1 - The company, Reshaping Energy, announced a financing plan through the placement of new H-shares, issuing 563,340 shares to raise approximately HKD 80 million, with a net amount of about HKD 78.3 million after expenses [1] - The placement price of HKD 142.00 represents a discount to the previous trading day's closing price and the average closing price over the last five trading days, although specific discount percentages were not provided due to missing data [1] - The newly issued shares account for approximately 0.65% of the existing issued share capital and will also represent about 0.65% of the enlarged share capital after completion [1] Group 2 - The funds raised will be allocated as follows: approximately HKD 39.15 million will be used to repay outstanding bank loans and lease liabilities to optimize the financial structure, while the remaining amount will be used for general corporate purposes [1] - The issuance was conducted under a general authorization granted by the shareholders' meeting and was completed on October 8, 2025 [1]

Core Viewpoint - The Hong Kong stock market's innovative pharmaceutical sector has shown a significant rebound this year, with a notable increase in refinancing activities, reflecting the ambition of domestic innovative drug companies to expand globally and leverage differentiated innovation advantages [1] Group 1: Financing Activities - The total refinancing amount in the Hong Kong market reached HKD 173.8 billion in the first half of the year, a year-on-year increase of 227%, surpassing the total for the entire year of 2024 [1] - More than 10 innovative pharmaceutical companies in the Hong Kong market have conducted placement financing, indicating a strong demand for capital to support research and development [1] - The company Xiansheng Pharmaceutical announced a placement financing plan to raise approximately HKD 1.5535 billion by issuing 121 million shares, reflecting its strategic move during a critical development phase [2][5] Group 2: Pricing and Market Response - The placement price of HKD 12.95 per share represents an approximately 8.03% discount to the closing price on September 1, 2025, and a 6.67% discount to the average closing price over the previous five trading days, which is within the common discount range of 5%-10% for stock issuances in the Hong Kong market [5][6] - The issuance of 121 million new shares will account for approximately 4.66% of the expanded total issued share capital, balancing the company's financing needs with shareholder interests [6] - Following the announcement, the stock price of Xiansheng Pharmaceutical experienced short-term fluctuations, but the trading volume exceeded 180 million shares, setting a new record since its listing, indicating strong market interest [7] Group 3: Company Performance and Strategy - Xiansheng Pharmaceutical has transformed into a leading innovative drug company, with a reported revenue growth of 15.1% to HKD 3.585 billion and an adjusted net profit increase of 21.1% to HKD 651 million, driven primarily by its innovative drug business [8] - The company has launched ten innovative drugs, with revenue from these drugs reaching HKD 2.776 billion, a 26% increase, accounting for 77.4% of total revenue [8] - Approximately 90% of the funds raised from the placement will be allocated to research and development, focusing on core areas such as neurology, oncology, autoimmune diseases, and anti-infection, which will enhance the company's global pipeline and validate its Biopharma value [9]